“Bevacizumab (Bev), irinotecan (IRI), folinic acid (FA), and 5-fluorouracil (FU) every 2 weeks (BIFF regimen) as first-line treatment for metastatic colorectal cancer (MCRC) patients (pts): The SICOG experience”

Comella, P; Massidda, B; Natale, D; Filippelli, G; Farris, A; Condemi, G; Tafuto, S; Vessia, G; Barberis, G

Risultato della ricerca: Paper

Lingua originaleEnglish
Stato di pubblicazionePublished - 2009

Cita questo

“Bevacizumab (Bev), irinotecan (IRI), folinic acid (FA), and 5-fluorouracil (FU) every 2 weeks (BIFF regimen) as first-line treatment for metastatic colorectal cancer (MCRC) patients (pts): The SICOG experience”. / Comella, P; Massidda, B; Natale, D; Filippelli, G; Farris, A; Condemi, G; Tafuto, S; Vessia, G; Barberis, G.

2009.

Risultato della ricerca: Paper

@conference{cb0d472329d54f2991f4e34a5a679820,
title = "“Bevacizumab (Bev), irinotecan (IRI), folinic acid (FA), and 5-fluorouracil (FU) every 2 weeks (BIFF regimen) as first-line treatment for metastatic colorectal cancer (MCRC) patients (pts): The SICOG experience”",
keywords = "bevacizumab, metastatic colorectal cancer",
author = "{Comella, P; Massidda, B; Natale, D; Filippelli, G; Farris, A; Condemi, G; Tafuto, S; Vessia, G; Barberis, G} and Sergio Palmeri",
year = "2009",
language = "English",

}

TY - CONF

T1 - “Bevacizumab (Bev), irinotecan (IRI), folinic acid (FA), and 5-fluorouracil (FU) every 2 weeks (BIFF regimen) as first-line treatment for metastatic colorectal cancer (MCRC) patients (pts): The SICOG experience”

AU - Comella, P; Massidda, B; Natale, D; Filippelli, G; Farris, A; Condemi, G; Tafuto, S; Vessia, G; Barberis, G

AU - Palmeri, Sergio

PY - 2009

Y1 - 2009

KW - bevacizumab, metastatic colorectal cancer

UR - http://hdl.handle.net/10447/45274

M3 - Paper

ER -